Education: MBBS, MD (Internal Medicine, Manipal), DM Medical & Hemato-Oncology (Gold Medalist),
PGDED(UK), FAGE, Diploma in Advanced Management of Oncological Diseases by Harvard Medical School Executive education
Dr. Venkatesh Kapu is a highly trained Medical Oncologist at Apollo Hospitals Health City, Arilova, Vizag, and Apollo Hospitals Ramnagar, Vizag, specializing in the diagnosis and comprehensive management of cancer and blood-related malignancies. He holds an MBBS, MD in Internal Medicine from Manipal, and DM in Medical & Hemato-Oncology, where he was a Gold Medalist, reflecting his strong academic performance and advanced expertise in oncology and hematology.
Dr. Kapu is committed to providing personalized, evidence-based cancer care using modern treatment approaches tailored to each patient's disease profile and individual needs. His areas of expertise include bone marrow transplantation and cellular therapies, offering advanced treatment options for selected hematological malignancies and other conditions requiring cellular-based therapies. He also has a special interest in immunotherapy, utilizing treatments that harness the body's immune system to recognize and fight cancer cells.
His expertise further includes precision therapy, where treatment strategies are guided by the molecular and genetic characteristics of a patient's cancer to support more targeted and individualized care. Dr. Kapu also places strong emphasis on supportive care, helping patients manage treatment-related side effects, maintain quality of life, and receive comprehensive care throughout their cancer treatment journey.
Fluent in English, Telugu, Hindi, and Kannada, Dr. Venkatesh Kapu believes in clear communication, compassionate care, and shared decision-making. He works closely with multidisciplinary oncology teams to develop comprehensive treatment plans focused on patient safety, clinical outcomes, and long-term well-being.
Worked as Senior Resident in TMH Mumbai for 3 years
Assistant and Associate professor for 3 years in Homibaba Cancer institute, Mumbai and Visakhapatnam
Completed more than 50 Bone marrow transplants and Cellular therapies in past 2years and treated more than 1 lakh patients with various oncology treatments
Special interest
Bone marrow transplantation and cellular therapies
Immunotherapy
Precision Therpy
Supportive Care
Memberships
ASCO
ISMPO
MASCC
ESMO
IANO
Awards & Achievements
Best Outgoing student and Goldmedalist in Homibaba university DM category of all Medical Branches
BEST Abstract AWARD: ASH 2021
Paper presentation for Clinical utility of BAL in febrile neutropenia patients with lung infiltrates.
Winner of TYCOON all india Quiz
Top four finalist in all india DM resident Exam, COPE,2023
Finalist representing west Zone in TYSA QUIZ 2022
Winner for best project in MHG conference for presenting about work on AML outpatient study at our institute
Was selected for CREDO 2023 and was part of programme and developed protocol A Phase III Randomized Study to compare two Different DOsing Strategies of RAsburicase in Adolescent and Adult Acute Leukaemia and High Grade Lymphomas with at Risk and Established Tumor Lysis Syndrome (DOoSRA Trail).
Rappourteur for consensus in immunotherapy in lung cancer, Dubai,2023
Delivered Talks at various national conference all over india as moderator/panelist and expert speaker and guest lectures in more than 250
conferences
Research & Publications
01
Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial-Lancet
02
Clinical Utility of Stepwise Bronchoalveolar Lavage Fluid Analysis in Diagnosing and Managing Lung Infiltrates in Leukemia/Lymphoma Patients With Febrile Neutropenia-JCO Global Oncology
03
Clinical Profile and Outcomes of Carcinoma Penis Patients Receiving Systemic Therapy at an Indian tertiary care Center: A Retrospective Observational Study-Clinical Genitourinary Cancer
04
Docetaxel-oxaliplatin-capecitabine/5 fluorouracil (DOC/F)followed by docetaxel versus Oxaliplatin-Capecitabine/5fluorouracil(CAPOX/mFOLFOX-7) in HER2 negative advanced gastric cancers-JNCI Cancer Spectrum
05
Acupuncture as a modality of treatment for chemotherapy-induced peripheral neuropathy in breast cancer: A phase 3 randomized controlled trial (ABC-CIPN)-abstract in JCO and manuscript already sent for publishing to other journal
06
VAMANA: A phase 2 study of low-dose bevacizumab plus CCNU in relapsed/recurrent glioblastoma.-JCO
07
Phase III randomized trial comparing neoadjuvant paclitaxel+platinum to 5-fluorouracil+platinum in esophageal/GEJ squamous cell carcinoma-JNCI
08
Metronomic Chemotherapy and Low-Dose Immunotherapy: An Intriguing Story-Chapter in Springer publication
09
Molecular features of Pregnancy Associated Breast Cancer from a tertiary care cancer centre in India-Abstract in Clinical Cancer Research.
10
Mixed Phenotypic Acute Leukemia -Clinical Presentation, Prognosis and Outcomes of Patients Treated with Acute Lymphoblastic Leukemia like Protocols a Multi-Institutional Study from India
11
Efficacy of Bispecific Antibodies Vs CAR-T in the Treatment of Extramedullary Disease and High-Risk Cytogenetics in Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis
12
The need of special care for adolescent and young adult (AYA) cancer survivors: Perspective from oncologists in India
13
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation
14
Bevacizumab plus erlotinib maintenance versus observation in advanced biliary tract cancers: Results from the phase II component of a prospective integrated phase II-phase III parallel design superiority clinical trial (BEER-BTC study)
15
Clinical Profile and Outcomes of Young Women with Denovo-metastatic Breast Cancer: Real-world data from a tertiary care Centre in India
16
Chemotherapy related pain in cancer pain book(CBS Publishers)
17
Role of oral metronomic chemotherapy and low dose immunotherapy in head and neck cancers publishing in springer publications
18
Integrating Immunotherapy (IO) in resectable non-small cell lung cancer (NSCLC): Excellence in Oncology Care (EIOC) 2023 Lung Cancer consensus guidelines
19
Liquid biopsy use in NSCLC and integrating targeted therapy in early-stage and locally advanced NSCLC: EIOC 2023 Lung Cancer consensus guidelines
20
Practice Patterns and Incidence of Febrile Neutropenia in Patients Receiving Triplet Drug Chemotherapeutic Regimens in GUT Cancers: Do We Need to Add WBC Growth Factors? (ForGeT GCSF Study)
21
Patient navigation improves treatment compliance in women with breast cancer: A prospective observational audit from India
22
Reviewer in International Journal of Breast cancer, Peer reviewer for CRST, IJMPO and Clinical Oncology Journals.
23
Is Principle Investigator and CO investigator for more than 20 clincial trials both investigator and pharma sponsored clinical trials.
24
CO-PI--Role of lactoferrin in cancer related anemia
25
PI --Docetaxel vs Carboplatin as radiosensitizer in Head And Neck cancer patients, unsuitable for cisplatin based chemoradiation
26
PI--A Phase III randomized controlled study comparing triple oral metronomic chemotherapy with low dose immunotherapy to standard intravenous
chemotherapy in patients with advanced platinum-sensitive head and neck squamous cell carcinoma in the first line palliative setting
27
CO-I--Hepatoid adenocarcinoma: Assessment of clinicopathological features and PD-L1 expression
28
CO-I-- Prospective registry for skeletal metastasis treated with palliative intent radiation
29
CO-I---Genotyping of Carbapenem resistant Enterobacterales and Aztreonam and ceftazidime/ avibactam synergy testing against MBL producing Enterobacterales in a Tertiary Cancer Care Centre, Visakhapatnam
30
CO-I--Phase III randomized controlled trial of sequential chemotherapy and radiotherapy versus concurrent chemoradiotherapy in adjuvant treatment of breast cancer (CONCERT)"
31
CO-I--Integration of Multi-modality imaging Protocols with emphAsis on CT in Image Guided Adaptive Brachytherapy (IGABT) for Cervical Cancer - EMBRACE III-IMPACT STUDY
32
PI-Phase III RCT comparing triplet neoadjuvant chemotherapy with neoadjuvant chemoradiation in patients with locally advanced resectable esophageal squamous carcinoma
33
CO-PI--A phase III randomized study of first line maintenance Hormonal therapy Versus observation in patients with estrogen or progesterone receptor positive High grade epithelial Ovarian cancer after completion of primary Treatment with surgery and platinum-based chemotherapy (H20study)
34
CO-I--Glioma outcomes and benchmark evaluation at HBCHRC, Vizag -GLOBE
35
CO-PI--Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Evixapodlin Administered as 2nd Line Monotherapy in Subjects with Advanced Non-Small Cell Lung Cancer Expressing PD-L1.
36
CO-PI--A PHASE III, MULTI CENTRE, RANDOMIZED, OPEN LABEL, ACTIVE CONTROLLED, PARALLEL GROUP, NON – INFERIORITY STUDY OF PYROTINIB PLUS CAPECITABINE COMPARED WITH LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER
37
CO-I--Retrospective analyses of endometrial cancer adjuvant therapy outcomes: Real world data from a single institution
38
CO-I Patient Navigation improves treatment compliance in women with breast cancer: An observational audit from India.
39
CO-I Induction Chemotherapy for Cervical Cancer: Practice Patterns Survey – A Questionnaire based study
40
CO-I A prospective multi-center study on practice, clinical outcomes, and toxicities in children with mature B-cell non-Hodgkin lymphoma treated with Rituximab-based chemotherapy regimen in India.
41
PI(IEC stage)- A multicentre Phase III randomized control trial to test the efficacy of targeted agents during induction and a response-adapted consolidation in adolescent and young adult patients with de-novo ALL
42
PI--The ABC-HCC Trial : A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage HepatoCellularCarcinoma.
Best Hospital Near me Chennai